Pharma
Targeting IL-23, Medicilon assists the development of a variety of new drugs for Psoriasis
With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop. From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again. In recent y...
Medicilon neural system disease models help our clients advance novel drug development
Medicilon Pharmacodynamics Department can deliver multiple nervous system models based on anti-depressants, anti-Alzheimer's drugs, sedative-hypnotic and anti-anxiety drugs, analgesics, anti-convulsant, anti-Parkinson's drugs, and anti-schizophrenia drugs. Those models can effectively e...
Guardtech Group hoping to end golden year with more success at SME National Business Awards
Suffolk contamination control experts looking to add Best Enterprising Business prize to epic 2024 awards haul at glitzy Wembley Stadium showpiece on 6 December ...
Analytics for clinical development strategy: Integrated optimization of an oncology program
Achieving a return on invested capital (ROIC) that exceeds the cost of capital remains a challenge for pharmaceutical R&D. To make progress, there needs to be consistent and rigorous modeling of the clinical and commercial determinants of ROIC. In the second of three articles, CRA’...
CMS’ Alzheimer’s NCD: Outlier or harbinger of increased scrutiny?
Aduhelm was the first FDA-approved disease-modifying treatment for Alzheimer’s, sparking debate among providers, regulators, and patients. Aduhelm received a controversial accelerated approval from the FDA in June 2021, a decision that balanced the lack of consensuses among the scientif...
Analytics for clinical development strategy: A unified approach to optimizing return on investment in R&D
Despite the rapid scientific advances with new targets, modalities, and biomarkers, the return on invested capital (ROIC) in novel therapeutics remains low. The problem stems from the large investment needed, high risks of failure, and long timelines until revenues can be realized. This...
Infertility - A public health concern
The World Health Organization (WHO) estimates that one out of six people globally are impacted by the inability to conceive a child. Over the last decade, countries around the world have seen a decline in total fertility rates, most notably in economically developed countries withi...
Glox Therapeutics awarded £1M PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant pathogens
Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects Glasgow, UK, 20 November...
COPD management: a critical look at gaps in pharmaceutical innovation
Chronic Obstructive Pulmonary Disease (COPD) presents a major global health challenge, marked by chronic respiratory decline and frequent exacerbations. Despite advances in treatment, comprehensive management strategies remain limited, revealing significant gaps in patient care. ...
Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024
EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies Validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer detection Data pr...